Eckert & Ziegler stock (DE0005659700): partnership with Thor Medical highlights lead-212 cancer therapy push

Eckert & Ziegler shares on Xetra traded moderately higher on 05/28/2026 after the German radiopharmaceutical group announced a collaboration and supply agreement with Norway’s Thor Medical to secure access to lead-212 for next-generation targeted cancer therapies.

Eckert & Ziegler shares in Germany drew investor attention on 05/28/2026 after the Berlin-based radiopharma specialist announced a collaboration and supply agreement with Norway’s Thor Medical to secure supplies of the medical radioisotope lead-212 for pharmaceutical partners developing targeted alpha therapies for cancer, according to an EQS corporate release dated 05/28/2026 and company information.

The company said in its 05/28/2026 EQS release that Thor Medical will supply lead-212 to Eckert & Ziegler for preclinical research and development activities and for the pharmaceutical industry, with the goal of enabling broader access to one of the most promising isotopes for the next generation of cancer treatments.

As part of the agreement, Thor Medical will use its production technology for lead-212 based on the decay of thorium-228, while Eckert & Ziegler plans to integrate this supply into its radiopharmaceutical services platform, positioning itself as a key partner for drug developers seeking alpha-emitting isotopes for targeted cancer therapies, according to the same 05/28/2026 EQS statement and related reporting from Reuters on 05/28/2026.

The stock traded around EUR 32 on Xetra in Frankfurt on 05/28/2026, with intraday moves of roughly 1–2 percent, reflecting a measured reaction as investors assessed the strategic implications of the new partnership for Eckert & Ziegler’s role in the growing targeted radiopharmaceuticals market, based on Xetra trading data as of 05/28/2026 from Deutsche Börse and price information reproduced on financial portals.

Germany remains the home base for Eckert & Ziegler, with the primary listing on Xetra under the ticker EUZ and regulatory oversight by BaFin, and the latest transaction underlines how German-listed life sciences companies are seeking to strengthen their positions in niche segments of oncology by securing long-term access to critical isotopes such as lead-212.

As of: 05/28/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Eckert & Ziegler
• Sector/industry: Radiopharmaceuticals and nuclear medicine technology
• Headquarters/country: Berlin, Germany
• Core markets: Europe, North America, Asia-Pacific
• Key revenue drivers: Medical radioisotopes, radiopharmaceutical services, industrial radiometry
• Home exchange/listing venue: Xetra (EUZ)
• Trading currency: EUR

Eckert & Ziegler: core business model

Eckert & Ziegler focuses on supplying medical radioisotopes and related services for cancer diagnostics and therapy, with sales primarily driven by its radiopharma and isotope technology solutions used by pharmaceutical firms, clinics, and industrial customers worldwide.

Industry trends and competitive position

The partnership with Thor Medical comes against the backdrop of a wider industry shift toward targeted radiopharmaceuticals, in which alpha-emitting isotopes like lead-212 are considered promising for delivering high-energy radiation directly to tumor cells while potentially sparing surrounding healthy tissue, according to sector analyses on radiotheranostics published by specialized healthcare research firms in 2025 and 2026.

By locking in a supply route for lead-212 via Thor Medical’s thorium-228 decay technology, Eckert & Ziegler aims to position itself more firmly as an infrastructure and service partner for pharma groups that are developing targeted alpha therapies, strengthening its competitive stance in a field where other isotope and radiopharma suppliers in Europe and North America are similarly working to secure access to scarce isotopes needed for clinical pipelines.

Conclusion

The announcement of a collaboration and supply agreement with Thor Medical to secure lead-212 underscores Eckert & Ziegler’s efforts to deepen its involvement in targeted radiopharmaceuticals and to support pharmaceutical partners working on alpha-emitting cancer therapies.

Within the broader industry trend toward precision oncology and radiotheranostics, the German-listed group is aiming to enhance its competitive position by combining its existing radioisotope and service infrastructure with new isotope supply channels, while investors will watch how such partnerships translate into project pipelines and potential long-term revenue streams.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.